WashUMedIBD Profile Banner
WashU Medicine Inflammatory Bowel Disease Center Profile
WashU Medicine Inflammatory Bowel Disease Center

@WashUMedIBD

Followers
505
Following
84
Media
55
Statuses
133

Improving quality of life for IBD patients locally and globally through an interdisciplinary approach including world-class patient care, research & education.

St Louis, MO, USA
Joined September 2017
Don't wanna be here? Send us removal request.
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
1️⃣ Welcome to #WUIBDCME25! 🎉.🔹 Multidisciplinary IBD conference in St. Louis @WashUMedGastro.🔹 Engaging talks on cutting-edge IBD management.🔹 Live Q&A + Networking—let’s advance IBD care together!🚀.@P_DeepakIBDMD @CiorbaGI #DrKayciHuff
Tweet media one
Tweet media two
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
5 months
Our 7th Annual WashU Medicine Multidisciplinary IBD CME Conference will take place on Sat., March 8, with Keynote Speakers, Dr. Edward V. Loftus, Jr., MD, Prof. Laurent Peyrin-Biroulet, and Dr. Louis Cohen. Register today! Email ibd@wustl.edu with any questions! @P_DeepakIBDMD
Tweet media one
1
3
10
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
5/ 📉 In real-world data, upadacitinib induced remission in some patients previously exposed to tofacitinib. 🧠 Mechanism and selectivity matter—UPA targets JAK1 more selectively, which may offer an edge in select cases.
Tweet media one
Tweet media two
0
0
1
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
4/ 🧬 JAKi therapy is intracellular, oral, and fast-acting! . 📋 Baseline labs (CBC, CMP, lipids), herpes zoster vaccination, and cardiovascular risk screening.
Tweet media one
Tweet media two
1
0
1
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
3/ 📈 In OCTAVE and U-ACHIEVE trials, both tofacitinib and upadacitinib achieved significant clinical and endoscopic remission. 🧪 Upadacitinib showed benefit even in biologic-experienced populations, reinforcing its role post-anti-TNF failure.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
0
1
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
2/ 💊 JAK inhibitors like tofacitinib and upadacitinib offer rapid symptom relief and mucosal healing in moderate to severe UC and CD. ⚠️ But their use demands vigilance for thrombotic and cardiovascular risk—screen before, monitor after.
Tweet media one
1
1
3
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
🎤 Welcome to the Gateway Gut Club Speaker Series featuring Dr. Raymond Cross (Mercy Medical Center, Maryland). 🧠 @Marylandibddoc ➡️ “JAKi in the (Black) Box: Using JAKi in Clinical Practice”
Tweet media one
Tweet media two
1
1
2
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
6/.JAK inhibitors are reshaping ASUC rescue therapy. 🧪In TACOS 🌮, tofacitinib 10 mg TID reduced colectomy rates at 90 days 📉. 🔍⚠️But safety is key➡️monitor for thrombotic events!.🌠The Future: HBOT for ASUC?
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
6
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
5/.📊 Choose based on contraindications, prior exposure, and center expertise. 🚽💉 Fecal loss of infliximab correlates with non-response in ASUC. 📉🧪 Low albumin and high CRP predict decreased drug exposure. ⏩🩺 Consider accelerated or intensified dosing in these cases.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
1
3
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
4/⏳Day 3 matters: if 🚫steroid response by then, initiate rescue ➡️IFX 💉, cyclosporine 💉, or JAK inhibitors 🚨. 🛟 Colectomy isn’t failure ✂️it can be life-saving
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
1
3
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
3/ 💊 Tofacitinib and upadacitinib show promise in steroid-refractory ASUC. 🌟Early remission is possible, but monitor closely for thrombosis risk ⚠️🩸.
Tweet media one
Tweet media two
1
2
5
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
2/🚫💊Use broad-spectrum antibiotics in ASUC unless C. difficile is confirmed. If positive ✅, treat with vancomycin or fidaxomicin only 💉—not metronidazole.
Tweet media one
Tweet media two
Tweet media three
1
1
5
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
1/Division Rounds: "Treatment of Acute Severe Ulcerative Colitis" by @Marylandibddoc .💫In ASUC, early recognition of high-risk features—📉📉Albumin ≤3 g/dL .🧪CRP ≥50 mg/L .🔦MES 3.🔍should prompt accelerated therapy ⏩ or surgical consult 🏥 .⚠️Delays can be fatal!
Tweet media one
Tweet media two
Tweet media three
Tweet media four
2
39
99
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
RT @DCharabaty: ⏳Don’t miss the EduSocial event of #DDW25 w 🌟 faculty !. 🤝Clinicians, patients, advocates, Let’s talk #IBD & collab for bet….
0
9
0
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
3 months
RT @WashUMedGastro: We are looking forward to our Annual WashU Advanced Endoscopy Course and Hands-on course for fellows. Delighted to host….
0
9
0
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
RT @kristin_gi_rd: The human behind so much of the organization & execution of the Washington University in St Louis IBD Center Multidiscip….
0
3
0
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
🔚 Last🎙️ @ChienHuanChen .🔦Surveillance colonoscopy—best practices? 🩺.✅ HD scopes > standard definition.✅ Dye chromoendoscopy (DCE) > standard white light.✅ Targeted biopsies (not random) unless high-risk (PSC, prior neoplasia)
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
5
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
1⃣2⃣🎙️ @CiorbaGI .Beyond standard IBD therapies—what works? 🤔.🔹 Curcumin, Qing Dai (CurQD), TUDCA, HBO therapy show promise.🔹 FMT, probiotics, LDN, CBD lack strong evidence.🔹 Gut-directed therapies = next frontier in IBD!
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
1
5
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
1⃣1⃣🎙️.Can mindfulness help in IBD? 🧘‍♂️.✅ Reduces stress, anxiety & depression.✅ Improves QOL.✅ May lower CRP, fecal calprotectin.Future of mindfulness in IBD? 🔮.🔹 Web-based MBIs show promise for remote therapy.🔹 Personalized stress-reduction plans could improve outcomes
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
1
3
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
RT @kristin_gi_rd: Had so much fun talking fitness for folks with IBD at the St Louis @CrohnsColitisFn MyIBD Learning Patient & Caregiver E….
0
4
0
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
RT @kristin_gi_rd: Thoughtful conversations among IBD MDs about use of GLP-1 meds in IBD patients. @WashUMedIBD @P_DeepakIBDMD #wuibdcme25….
0
3
0
@WashUMedIBD
WashU Medicine Inflammatory Bowel Disease Center
4 months
🔟🎙️@P_DeepakIBDMD .🧐Why does visceral fat impact IBD? .🔹 Acts as an autocrine organ⏩inflammation.🔹 Alters💊distribution & lymphatic🌊.🔹 Shares⛓️ inflammatory🛣️ w/ IBD. ⚖️Can weight loss improve IBD outcomes? .✅ Exercise⬇️ VAT.🥗diet shows promise.✅ GLP-1s & bariatric✂️
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
4
13